The headline has been corrected to state that Biocept's first quarter revenues decreased, not increased, 20 percent.

NEW YORK (GenomeWeb) – Newly publicly traded firm Biocept yesterday reported a 20 percent drop year over year in its first quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based firm said that revenues shrank to $28,275 for the three months ended March 31, compared to $35,154 in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.